PHARMACEUTICAL TECHNOLOGY
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
Table of contents
- 4
-
Open Alliance to Provide Bioavailability Solutions An industry round table with Catalent and BASF| 2012
- 5
-
Solid Dispersions by Hot-Melt Extrusion The advantages and disadvantages of hot-melt extrusion in solid dispersion formulations| 2012
- 6
-
Strategies for High-Containment An industry roundtable featuring SAFC, Euticals, Metrics, Cambrex, Carbogen Amcis, and Ferro Pfanstiehl| 2012
- 8
-
Lipophilic Excipients Streamlining the structure, nomenclature and functionality of excipients| 2012
- 10
-
Bioavailability Enhancement A Soluplus® case study of itraconazole| 2012
- 12
-
Joint Regulatory ConferencesJohnson, R. et al. | 2012
- 12
-
Lipid-Based Formulations A Johnson & Johnson viewpoint| 2012
- 12
-
Making API Synthesis GreenerMoody, T. / Brown, G. et al. | 2012
- 13
-
Fundamental Approaches to Performance, Stability and Manufacture Bend Research on optimizing spray-drying approaches| 2012
- 14
-
Europe Hones in on Antitrust ViolationsSutton, S. et al. | 2012
- 15
-
Addressing the Solubility Challenge A Q&A with Karl Kolter, Head of Pharmaceutical Excipients R&D at BASF| 2012
- 16
-
Developing the Optimal Solid FormIgo, D. / Carino, S. et al. | 2012
- 16
-
Compliant or Contraband?Control, a Senior Compliance Officer et al. | 2012
- 18
-
Achieving Process Understanding and Control in Film CoatingVan Ness, E. / Schad, B. / Riley, T. et al. | 2012
- 22
-
Excipients in Tastemasking A Q&A with BASF| 2012
- 26
-
The Project Management of Project Management-Building the ISPE Pharmaceutical Project Management ``Playbook''Melton, T. et al. | 2012
- 30
-
Moving to Risk-Based InspectionsVan Arnum, P. et al. | 2012
- 30
-
Campaign Mounts to Curb Counterfeit DrugsWechsler, J. et al. | 2012
- 34
-
Temperature-Controlled ShippersForcinio, H. et al. | 2012
- 34
-
Weighing Access and AffordabilityKaitin, K.I. / Cohen, J.P. et al. | 2012
- 38
-
Process Analytical Technology: Charting Progress in Data AnalysisWard, D. et al. | 2012
- 42
-
Future Innovation in Drug Delivery| 2012
- 46
-
Classifying Rouge Helps Define Remediation ProceduresAnderson, J. et al. | 2012
- 48
-
Achieving Stereoselectivity in APIs and Pharma IntermediatesVan Arnum, P. et al. | 2012
- 52
-
Numerical Simulation of Tablet CoatingToschkoff, G. / Suzzi, D. / Adam, S. et al. | 2012
- 56
-
2,4,6-Tribromoanisole and 2,4,6-TrichloroanisoleParenteral Drug Association et al. | 2012
- 64
-
Early Development GMPs for Stability: An Industry Perspective (Part IV)Acken, B. / Alasandro, M. / Colgan, S. et al. | 2012
- 72
-
Correlating Product Lifecycle and Manufacturing Site Characteristics with Critical-to-Quality Product DeviationsDomike, R.D. / Macher, J.T. / Barone, P.W. et al. | 2012
- 76
-
USP Further Strengthes Quality Standards for HeparinSzajek, A.Y. / Morris, T.S. et al. | 2012
- 78
-
The Macro ViewMiller, J. et al. | 2012
- 90
-
Technology Transfer: Protecting the True Public InterestGreenwood, J. et al. | 2012